Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 109

1.

Acceptance of pharmaceutical cannabis substitution by cannabis using patients with schizophrenia.

van Amsterdam J, Vervloet J, de Weert G, Buwalda VJA, Goudriaan AE, van den Brink W.

Harm Reduct J. 2018 Sep 20;15(1):47. doi: 10.1186/s12954-018-0253-7.

2.

Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function.

Morgan CJA, Freeman TP, Hindocha C, Schafer G, Gardner C, Curran HV.

Transl Psychiatry. 2018 Sep 5;8(1):181. doi: 10.1038/s41398-018-0191-x.

3.

Effect of Cannabidiol on Medial Temporal, Midbrain, and Striatal Dysfunction in People at Clinical High Risk of Psychosis: A Randomized Clinical Trial.

Bhattacharyya S, Wilson R, Appiah-Kusi E, O'Neill A, Brammer M, Perez J, Murray R, Allen P, Bossong MG, McGuire P.

JAMA Psychiatry. 2018 Aug 29. doi: 10.1001/jamapsychiatry.2018.2309. [Epub ahead of print]

PMID:
30167644
4.

A Brief Background on Cannabis: From Plant to Medical Indications.

Klumpers LE, Thacker DL.

J AOAC Int. 2018 Aug 23. doi: 10.5740/jaoacint.18-0208. [Epub ahead of print]

PMID:
30139415
5.

Probing the endocannabinoid system in healthy volunteers: Cannabidiol alters fronto-striatal resting-state connectivity.

Grimm O, Löffler M, Kamping S, Hartmann A, Rohleder C, Leweke M, Flor H.

Eur Neuropsychopharmacol. 2018 Jul;28(7):841-849. doi: 10.1016/j.euroneuro.2018.04.004. Epub 2018 Jun 7.

PMID:
29887287
6.

Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview.

Mandolini GM, Lazzaretti M, Pigoni A, Oldani L, Delvecchio G, Brambilla P.

Epidemiol Psychiatr Sci. 2018 Aug;27(4):327-335. doi: 10.1017/S2045796018000239. Epub 2018 May 23.

PMID:
29789034
7.

An assessment of concurrent cannabidiol and Δ⁹-tetrahydrocannabinol administration in place aversion and taste avoidance conditioning.

Hempel BJ, Clasen MM, Nelson KH, Woloshchuk CJ, Riley AL.

Exp Clin Psychopharmacol. 2018 Apr;26(2):205-213. doi: 10.1037/pha0000188.

PMID:
29648861
8.

The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial.

Boggs DL, Surti T, Gupta A, Gupta S, Niciu M, Pittman B, Schnakenberg Martin AM, Thurnauer H, Davies A, D'Souza DC, Ranganathan M.

Psychopharmacology (Berl). 2018 Jul;235(7):1923-1932. doi: 10.1007/s00213-018-4885-9. Epub 2018 Apr 5.

PMID:
29619533
9.

Novel treatment options in depression and psychosis.

Ceskova E, Silhan P.

Neuropsychiatr Dis Treat. 2018 Mar 13;14:741-747. doi: 10.2147/NDT.S157475. eCollection 2018. Review.

10.

Cannabidiol, an Adjunct Player in the Antipsychosis Arsenal.

Bassir Nia A, Hurd YL.

Am J Psychiatry. 2018 Mar 1;175(3):197-198. doi: 10.1176/appi.ajp.2017.17121295. No abstract available.

PMID:
29490489
11.

Potency of Δ9 -tetrahydrocannabinol and other cannabinoids in cannabis in England in 2016: Implications for public health and pharmacology.

Potter DJ, Hammond K, Tuffnell S, Walker C, Di Forti M.

Drug Test Anal. 2018 Apr;10(4):628-635. doi: 10.1002/dta.2368. Epub 2018 Feb 27.

PMID:
29441730
12.

The Influence of DAT1, COMT, and BDNF Genetic Polymorphisms on Total and Subregional Hippocampal Volumes in Early Onset Heavy Cannabis Users.

Batalla A, Lorenzetti V, Chye Y, Yücel M, Soriano-Mas C, Bhattacharyya S, Torrens M, Crippa JAS, Martín-Santos R.

Cannabis Cannabinoid Res. 2018 Feb 1;3(1):1-10. doi: 10.1089/can.2017.0021. eCollection 2018.

13.

Commentary on "The Potential of Cannabidiol Treatment for Cannabis Users With Recent-Onset Psychosis".

McGuire P, Englund A, Bhattacharyya S.

Schizophr Bull. 2018 Jan 13;44(1):18-19. doi: 10.1093/schbul/sbx124. No abstract available.

PMID:
29346673
14.

Cannabis, cannabinoids, and health.

Lafaye G, Karila L, Blecha L, Benyamina A.

Dialogues Clin Neurosci. 2017 Sep;19(3):309-316. Review.

15.

Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial.

McGuire P, Robson P, Cubala WJ, Vasile D, Morrison PD, Barron R, Taylor A, Wright S.

Am J Psychiatry. 2018 Mar 1;175(3):225-231. doi: 10.1176/appi.ajp.2017.17030325. Epub 2017 Dec 15.

PMID:
29241357
16.

Pharmacological Foundations of Cannabis Chemovars.

Lewis MA, Russo EB, Smith KM.

Planta Med. 2018 Mar;84(4):225-233. doi: 10.1055/s-0043-122240. Epub 2017 Nov 21.

PMID:
29161743
17.

The effects of cannabidiol on persecutory ideation and anxiety in a high trait paranoid group.

Hundal H, Lister R, Evans N, Antley A, Englund A, Murray RM, Freeman D, Morrison PD.

J Psychopharmacol. 2018 Mar;32(3):276-282. doi: 10.1177/0269881117737400. Epub 2017 Oct 31.

PMID:
29086614
18.

The Potential of Cannabidiol Treatment for Cannabis Users With Recent-Onset Psychosis.

Hahn B.

Schizophr Bull. 2018 Jan 13;44(1):46-53. doi: 10.1093/schbul/sbx105.

PMID:
29083450
19.

Long-term Administration of Antipsychotic Drugs in Schizophrenia and Influence of Substance and Drug Abuse on the Disease Outcome.

Werner FM, Covenas R.

Curr Drug Abuse Rev. 2017;10(1):19-24. doi: 10.2174/1874473710666171020104524. Review.

PMID:
29065847
20.

Phytocannabinoids modulate emotional memory processing through interactions with the ventral hippocampus and mesolimbic dopamine system: implications for neuropsychiatric pathology.

Hudson R, Rushlow W, Laviolette SR.

Psychopharmacology (Berl). 2018 Feb;235(2):447-458. doi: 10.1007/s00213-017-4766-7. Epub 2017 Oct 24. Review.

PMID:
29063964

Supplemental Content

Loading ...
Support Center